Cocrystal Pharma (COCP) Fundamental Analysis: Revenue, Earnings & Valuation

3.86 / 10

Netural

Fundamental quality scores 3.9/10, indicating concerns. Positive factors include a healthy current‑liabilities‑to‑total‑liabilities ratio (54.7%) and strong interest coverage (15.6×). Negative drivers are low asset‑to‑market value and modest revenue‑to‑market value, leading to a constrained outlook.

Analysis Checks(9/10)

Revenue-MV

Value-0.28

Score3/3

Weight45.60%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.63%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-5.20%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value54.74

Score2/3

Weight1.76%

1M Return0.36%

PB-ROE

Value0.15

Score2/3

Weight42.53%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.17

Score3/3

Weight3.99%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-5.28%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.25%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-5.00%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight20.72%

1M Return4.00%

Is COCP undervalued or overvalued?

COCP scores 3.86/10 on fundamentals and holds a Fair valuation at present. Backed by its -111.40% ROE, 0.00% net margin, -2.25 P/E ratio, 3.14 P/B ratio, and 54.65% earnings growth, these metrics solidify its Netural investment rating.